Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
Evolutionary Oncology: A New Research Validates This Approach in Preclinical Models
/in Immunotherapy, Preclinical Research/by MaxResearchers at Trinity College Dublin and Moffitt Cancer Center have uncovered a promising prostate cancer breakthrough: radiation-resistant tumor cells become unexpectedly vulnerable to attack by natural killer (NK) immune cells, presenting a strategic “evolutionary double-bind” that could transform treatment approaches. This discovery challenges traditional views of therapy resistance, showing that when prostate cancer cells adapt […]
UPDATE: VIR-5500 Results From Phase 1 Trial Look Very Promising
/in Clinical Trial, Metastatic, Phase 1/by MaxRecent clinical data from a Phase 1 dose-escalation trial highlight VIR-5500 as a highly promising therapeutic candidate for patients with heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is a dual-masked, bispecific T-cell engager designed to selectively target the prostate-specific membrane antigen (PSMA) while minimizing systemic toxicity. The therapy employs a specialized PRO-XTEN masking technology […]
A New Frontier: Magnetic Nanoparticle Hyperthermia for Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxIn November 2025, Mayo Clinic in Rochester, Minnesota installed the first magnetic nanoparticle hyperthermia system in the United States for cancer research. The first patient was treated in December 2025, marking a major step toward bringing a long‑overlooked concept into the modern, heavily pretreated cancer landscape. Hyperthermia, the therapeutic use of heat, has been studied […]
Genomic Alterations and LuPSMA Outcomes in mCRPC: A Prognostic Insight
/in Retrospective studies/by MaxGenomic alterations like TP53, PTEN, and RB1 mutations are prevalent in metastatic castration-resistant prostate cancer (mCRPC), yet their impact on response to 177Lu-PSMA-617 (LuPSMA, Pluvicto) radioligand therapy remains underexplored. A recent retrospective study published in the Journal of Nuclear Medicine analyzed 72 mCRPC patients treated with at least one cycle of LuPSMA between October 2022 […]
FDA Abandons Two-Trial Standard: Implications for Drug Development
/in FDA approvals/by MaxThe FDA announced on February 18, 2026, that it will no longer require two pivotal clinical trials for new drug approvals, establishing a single-trial approach as the default standard. In a New England Journal of Medicine perspective, FDA leaders argued that the “two-trial dogma”, unchallenged since the 1960s, is obsolete given advances in biology, statistical […]
Ultrasound Nanobubbles Crack Prostate Cancer’s Collagen Fortress Improving Immunotherapy Penetration
/in Delivery, Immunotherapy, Preclinical Research/by MaxResearchers at Case Western Reserve University used tiny ultrasound-activated nanobubbles to dismantle the tough collagen walls that shield solid tumors from treatments. These “fortresses” made of stiff, crosslinked collagen block immune cells and drugs from reaching cancer cells deep inside, a major hurdle in fighting aggressive tumors like prostate cancer. The nanobubbles, filled with inert […]
SHR-4394: Phase 1/2 Trial Explores PSMA-Targeted ADC Combination Therapies in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA Phase 1/2 clinical trial (NCT07407283) is investigating SHR-4394, a novel PSMA-targeted antibody-drug conjugate (ADC), in combination with other anticancer treatments for patients with advanced prostate cancer. SHR-4394 is designed to recognize prostate-specific membrane antigen (PSMA), a protein commonly expressed on prostate cancer cells, and deliver a cytotoxic payload directly to the tumor. Unlike PSMA-targeted […]
BG-C0979: Pioneering Phase 1 Trial Targets ADAM9 in Advanced Solid Tumors, Including CRPC
/in Clinical Trial, Metastatic, Non-Metastatic, Phase 1, Phase 1/by MaxA first-in-human Phase 1 clinical trial is underway to evaluate BG-C0979, a novel antibody-drug conjugate (ADC) designed for adults with advanced solid tumors. This open-label study focuses on assessing the drug’s safety, tolerability, pharmacokinetics, and early signs of antitumor activity through dose escalation and potential expansion phases. BG-C0979 targets ADAM9, a disintegrin and metalloproteinase enzyme […]